Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Repertoire Immune Medicines
With
This is a first-in-human, open-label, multicenter, dose escalation study designed to determine the safety and tolerability of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors or lymphomas. The study will include 2 dosing periods: A Dose Escalation (Phase 1) followed by an Expansion (Phase 2).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted